Afghanistan vs Libya: Statin use vs. average non-HDL cholesterol levels
Afghanistan
3.1
in 2018
Libya
3.1
in 2018
Afghanistan rank
134th
Libya rank
134th
Statin use vs. average non-HDL cholesterol levels over time
- Afghanistan
- Libya
How they compare
Afghanistan currently reports 3.1 against 3.1 in Libya, a difference of 0.
Across all 39 years both countries report, Libya has been ahead every year.
Afghanistan ranks 134th and Libya ranks 134th of 191 countries.
Libya has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Afghanistan | Libya | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.98 | 3.54 | 0.56 | Libya |
| 1990s | 3.1 | 3.6 | 0.5 | Libya |
| 2000s | 3.1 | 3.44 | 0.34 | Libya |
| 2010s | 3.1 | 3.19 | 0.0889 | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Afghanistan or Libya?
- Afghanistan, at 3.1 against 3.1 in Libya as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Afghanistan and Libya?
- 0, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Libya?
- 39 years are reported by both, from 1980 to 2018.
- How do Afghanistan and Libya rank globally for statin use vs. average non-hdl cholesterol levels?
- Afghanistan ranks 134th and Libya ranks 134th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.